Foreign Filer Report • Feb 13, 2025
Foreign Filer Report
Open in ViewerOpens in native device viewer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
For the month of February 2025
Commission File Number 001-36187
(Translation of Registrant's Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel (Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Evogene Ltd. (the "Registrant" or the "Company") hereby announces that the shareholders of the Company approved the proposal brought before the special general meeting of shareholders held on February 12, 2025 (following a one-week adjournment from the original meeting date) (the "Meeting"), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission ("SEC"), on December 30, 2024, and sent in connection with the Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
EVOGENE LTD. (Registrant)
Date: February 12, 2025
By: /s/ Yaron Eldad
Yaron Eldad Chief Financial Officer
——————————————
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.